Assessment of pharmacokinetic parameters of lupeol in Ficus religiosa L. extract after oral administration of suspension and solid lipid nanoparticles to Wistar rats

2017 ◽  
Vol 41 ◽  
pp. 58-67 ◽  
Author(s):  
Karunanidhi Priyanka ◽  
Ramoji Kosuru ◽  
Raju Prasad Sharma ◽  
Puran Lal Sahu ◽  
Sanjay Singh
Keyword(s):  
Oral Administration ◽  
Solid Lipid Nanoparticles ◽  
Wistar Rats ◽  
Lipid Nanoparticles ◽  
Pharmacokinetic Parameters ◽  
Ficus Religiosa ◽  
Solid Lipid

scholarly journals Pharmacokinetic and Tissue Distribution Study of Solid Lipid Nanoparticles of Zidovudine in Rats

2014 ◽  
Vol 2014 ◽  
pp. 1-7 ◽  
Author(s):  
Shah Purvin ◽  
Parameswara Rao Vuddanda ◽  
Sanjay Kumar Singh ◽  
Achint Jain ◽  
Sanjay Singh
Keyword(s):  
Oral Administration ◽  
Tissue Distribution ◽  
Solid Lipid Nanoparticles ◽  
High Performance ◽  
Lipid Nanoparticles ◽  
Peroral Administration ◽  
Pharmacokinetic Parameters ◽  
Distribution Study ◽  
Solid Lipid ◽  
Tissue Distribution Study

Zidovudine-loaded solid lipid nanoparticles (AZT-SLNs) and zidovudine in solution were prepared and administered in rats. The aim of this research was to study whether the bioavailability of zidovudine can be improved by AZT-SLNs perorally to rats as compared to oral administration of zidovudine. Zidovudine was determined in plasma and tissues by reverse phase high performance liquid chromatography. The pharmacokinetic parameters of zidovudine were determined after peroral administration: area under curve of concentration versus time (AUC) for AZT-SLNs was 31.25% greater than AZT solution; meanwhile mean resident time (MRT) was found to be 1.83 times higher for AZT-SLNs than AZT solution. Elimination half life of zidovudine was also increased for SLN formulation. Tissue distribution pattern of zidovudine was changed in case of AZT-SLNs. AUC of zidovudine in brain and liver was found to be approximately 2.73 and 1.77 times higher in AZT-SLNs than AZT solution, respectively, indicating that AZT-SLNs could cross blood brain barrier. Distribution of zidovudine was approximately 0.95 and 0.86 times lesser in heart and kidney, respectively. It can be concluded from the study that oral administration of AZT-SLNs modifies the plasma pharmacokinetic parameters and biodistribution of zidovudine.

Ganoderic acid -loaded solid lipid nanoparticles ameliorate d-galactosamine induced hepatotoxicity in Wistar rats

2019 ◽  
Vol 50 ◽  
pp. 48-56
Author(s):  
Habiba Shafique ◽  
Abdul Ahad ◽  
Washim Khan ◽  
Muzamil Yaqub Want ◽  
Prakash Chandra Bhatt ◽  
...  
Keyword(s):  
Solid Lipid Nanoparticles ◽  
Wistar Rats ◽  
Lipid Nanoparticles ◽  
Ganoderic Acid ◽  
Solid Lipid

Encapsulating Rifampicin into SLNs: A Viable Option for Managing its Bioavailability Issues Upon Co-Delivery with Isoniazid

2020 ◽  
Vol 17 (4) ◽  
pp. 343-347
Author(s):  
Harinder Singh ◽  
Ruchi Sood ◽  
Tridib Chaira ◽  
Alka Khanna ◽  
Dilip J Upadhaya ◽  
...  
Keyword(s):  
Plasma Concentration ◽  
Oral Administration ◽  
Solid Lipid Nanoparticles ◽  
Lipid Nanoparticles ◽  
Fixed Dose ◽  
Acidic Ph ◽  
Viable Option ◽  
Time Points ◽  
Solid Lipid

Background: Rifampicin is known to degrade at the acidic pH of the stomach, especially in the presence of isoniazid. Although isoniazid also degrades partially, its degradation is reversible. Objective: Presently, we provide a proof of the fact that the simultaneous oral administration of rifampicin (RIF), upon incorporation into solid lipid nanoparticles (RIF-SLNs), with isoniazid (INH) overcomes its INH-induced degradation and improves its oral bioavailability in rats. Methods: Solid lipid nanoparticles of RIF (RIF-SLNs) were prepared using a novel and patented method. The effect of INH was investigated on in vivo bioavailability of RIF both in its free and encapsulated (RIF-SLNs) form, after oral administration to rats. Results: Cmax and AUC0-∞ of RIF increased 158 % and 125 %, respectively, upon incorporation into SLNs versus free RIF when combined with INH. The Tmax decreased from 5.67 h to 3.3 h, and the plasma concentration of RIF remained above its MIC (8 μg/ml) at all the tested time points starting with 15 min, when administered as RIF-SLNs in combination with INH. Conclusions: The results confirm the scope of combining RIF-SLNs with INH to overcome the bioavailability of free RIF when combined with INH, especially in fixed dose combinations.

scholarly journals Solid lipid nanoparticles modified with stearic acid–octaarginine for oral administration of insulin

2012 ◽  
pp. 3333 ◽  
Author(s):  
Huixia Lv Hui-Xia ◽  
Zhen-Hai Zhang ◽  
Yin-long Zhang ◽  
Xu Wang ◽  
Xi-Ru Xu ◽  
...  
Keyword(s):  
Oral Administration ◽  
Stearic Acid ◽  
Solid Lipid Nanoparticles ◽  
Lipid Nanoparticles ◽  
Solid Lipid
Sign in / Sign up

Export Citation Format

Share Document